Xact Kapitalforvaltning AB raised its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 261,826 shares of the biopharmaceutical company’s stock after buying an additional 11,835 shares during the quarter. Xact Kapitalforvaltning AB’s holdings in Gilead Sciences were worth $19,739,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently bought and sold shares of the business. Handelsbanken Fonder AB lifted its position in Gilead Sciences by 19.4% in the first quarter. Handelsbanken Fonder AB now owns 239,870 shares of the biopharmaceutical company’s stock valued at $18,084,000 after buying an additional 39,000 shares during the last quarter. Gables Capital Management Inc. acquired a new stake in shares of Gilead Sciences during the first quarter worth about $1,228,000. Atlantic Trust Group LLC lifted its position in shares of Gilead Sciences by 9.4% during the first quarter. Atlantic Trust Group LLC now owns 185,521 shares of the biopharmaceutical company’s stock worth $13,988,000 after purchasing an additional 15,939 shares in the last quarter. Doheny Asset Management CA lifted its position in shares of Gilead Sciences by 47.4% during the first quarter. Doheny Asset Management CA now owns 35,006 shares of the biopharmaceutical company’s stock worth $2,639,000 after purchasing an additional 11,255 shares in the last quarter. Finally, NEXT Financial Group Inc lifted its position in shares of Gilead Sciences by 75.0% during the first quarter. NEXT Financial Group Inc now owns 6,939 shares of the biopharmaceutical company’s stock worth $523,000 after purchasing an additional 2,974 shares in the last quarter. 77.60% of the stock is currently owned by institutional investors.
Get Gilead Sciences alerts:Several brokerages have recently issued reports on GILD. BidaskClub cut shares of Gilead Sciences from a “sell” rating to a “strong sell” rating in a research report on Friday, May 4th. Barclays reduced their price target on shares of Gilead Sciences from $95.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, May 2nd. Leerink Swann set a $72.00 price target on shares of Gilead Sciences and gave the stock a “market perform” rating in a research report on Wednesday, May 2nd. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 2nd. Finally, Zacks Investment Research cut shares of Gilead Sciences from a “buy” rating to a “hold” rating in a research report on Monday, May 7th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $88.00.
In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $68.13, for a total value of $3,406,500.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $209,006,625.06. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director John Francis Cogan sold 5,833 shares of the stock in a transaction that occurred on Friday, March 23rd. The shares were sold at an average price of $75.02, for a total value of $437,591.66. Following the completion of the sale, the director now directly owns 58,452 shares of the company’s stock, valued at $4,385,069.04. The disclosure for this sale can be found here. Insiders sold 185,001 shares of company stock worth $13,226,824 over the last quarter. 1.16% of the stock is currently owned by insiders.
Shares of Gilead Sciences stock opened at $69.06 on Tuesday. The company has a market capitalization of $91.32 billion, a price-to-earnings ratio of 8.07, a P/E/G ratio of -6.11 and a beta of 1.15. Gilead Sciences, Inc. has a 52 week low of $64.02 and a 52 week high of $89.54. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.75 and a current ratio of 2.84.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $1.48 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.67 by ($0.19). The company had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.40 billion. Gilead Sciences had a net margin of 14.03% and a return on equity of 45.49%. The business’s revenue for the quarter was down 21.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.23 earnings per share. analysts anticipate that Gilead Sciences, Inc. will post 5.75 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, June 28th. Shareholders of record on Friday, June 15th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $2.28 annualized dividend and a yield of 3.30%. Gilead Sciences’s dividend payout ratio is currently 26.64%.
Gilead Sciences Profile
No comments:
Post a Comment